US23284F1057
© Globe Newswire
04.02.2026
CTMX
LISTED
NASDAQ
CytomX Therapeutics to Present at Upcoming February Conferences
News Preview
SOUTH SAN FRANCISCO, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following conferences in February....
Themefolio
Profiler
Peergroup
© Globe Newswire
25.11.2025
CTMX
LISTED
NASDAQ
CytomX Therapeutics to Present at Upcoming December Investor Conferences
News Preview
SOUTH SAN FRANCISCO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following investor conferences in December....
Themefolio
Profiler
Peergroup
© Globe Newswire
13.11.2025
CTMX
LISTED
NASDAQ
CytomX Therapeutics to Present at the Jefferies London Healthcare Conference
News Preview
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a fireside chat at the Jefferies Global Healthcare Conference in London...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Globe Newswire
06.11.2025
CTMX
LISTED
NASDAQ
CytomX Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update
News Preview
- CX-2051 Phase 1 data update on track for Q1 2026 -...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
23.01.2026
© Globe Newswire
04.11.2025
CTMX
LISTED
NASDAQ
CytomX Therapeutics to Present CX-801 Phase 1 Monotherapy Biomarker Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
News Preview
- CX-801 (PROBODY® interferon alpha-2b) Phase 1 data demonstrate activation of tumor-selective interferon signaling in patients with advanced melanoma -...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.10.2025
CTMX
LISTED
NASDAQ
CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025
News Preview
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report third quarter financial results on Thursday, November 6, 2025, after the close of U.S. markets. Following the announcement, the Company wil...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.10.2025
CTMX
LISTED
NASDAQ
CytomX Therapeutics Appoints Rachael Lester as Chief Business Officer
News Preview
Leadership team addition to drive strategic long-term value creation and partnering strategy Leadership team addition to drive strategic long-term value creation and partnering strategy...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.08.2025
CTMX
LISTED
NASDAQ
CytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update
News Preview
- May 12, 2025 announcement of positive interim data from ongoing Phase 1 study of CX-2051 (EpCAM Antibody Drug Conjugate) in patients with advanced colorectal cancer (CRC) -...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.05.2025
CTMX
LISTED
NASDAQ
CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference
News Preview
SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.05.2025
CTMX
LISTED
NASDAQ
CytomX Announces Positive Interim Data From Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate (CX-2051) Candidate in Patients with Advanced Colorectal Cancer (CRC)
News Preview
- 28% confirmed response rate (5/18) per RECIST v1.1 in unselected patients across doses prioritized for expansion (7.2, 8.6 and 10 mg/kg Q3W) -...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.05.2025
CTMX
LISTED
NASDAQ
CytomX Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update
News Preview
- Announced Positive Interim Data From Ongoing Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate (CX-2051) in Patients with Advanced Colorectal Cancer (CRC) -...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.05.2025
CTMX
LISTED
NASDAQ
CytomX Therapeutics to Report First Quarter 2025 Financial Results on May 12, 2025
News Preview
SOUTH SAN FRANCISCO, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report first quarter financial results on Monday, May 12, 2025, before the open of the U.S. markets. Following the announcement, the Company will h...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
06.03.2025
CTMX
LISTED
NASDAQ
CytomX Therapeutics Announces 2024 Financial Results and Provides Business Update
News Preview
- Continued progress with lead program, CX-2051 (EpCAM PROBODY® Topo-1 ADC), in Phase 1a study in advanced colorectal cancer with initial Phase 1a clinical data to be presented in 1H 2025 -...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.03.2025
CTMX
LISTED
NASDAQ
CytomX Therapeutics to Present at the Barclays 27th Annual Global Healthcare Conference
News Preview
SOUTH SAN FRANCISCO, Calif., March 05, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will present at the Barclays 27th Annual Global Healthcare Conference on Wednesday, March 1...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.11.2024
CTMX
LISTED
NASDAQ
CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference
News Preview
SOUTH SAN FRANCISCO, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a fireside chat at the 36th Annual Piper Sandler Healthcare Conference o...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.09.2024
CTMX
LISTED
NASDAQ
CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors
News Preview
SOUTH SAN FRANCISCO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that the first patient has been dosed with CX-801 monotherapy in a Phase 1 study (NCT06462794) in patients with solid tumors. CX-801 is a dually-m...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.06.2024
CTMX
LISTED
NASDAQ
CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
News Preview
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Immune Cel...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.06.2024
CTMX
LISTED
NASDAQ
CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer
News Preview
SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the promotion of Chris Ogden to Chief Financial Officer effective June 15, 2024....
Themefolio
Profiler
Peergroup
© Globe Newswire
22.05.2024
CTMX
LISTED
NASDAQ
CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference
News Preview
SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will present at the Jefferies Global Healthcare Conference on Thursday, June 6, 2...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.05.2024
CTMX
LISTED
NASDAQ
CytomX Therapeutics Announces New Employment Inducement Grants
News Preview
SOUTH SAN FRANCISCO, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that on May 15, 2024, the Company granted two new employees options to purchase a total of 130,000 shares of the Company’s common stock at an exercise price per...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.05.2024
CTMX
LISTED
NASDAQ
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab)
News Preview
- CX-801 is a dually masked, conditionally activated IFNα2b cytokine designed using the CytomX Probody® Therapeutic Platform -...
Themefolio
Profiler
Peergroup
© Newsfile
28.05.2020
CTMX
LISTED
NASDAQ
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of CytomX Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 20, 2020 - CTMX
News Preview
New York, New York--(Newsfile Corp. - May 27, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of CytomX Therapeutics, Inc. (NASDAQ: CTMX) ("CytomX") between May 17, 2018 and May 13, 2020. You are hereby notified that a securities class action law...
Themefolio
Profiler
Peergroup
© Newsfile
27.05.2020
CTMX
LISTED
NASDAQ
CTMX ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of July 20, 2020 in the Class Action Filed on Behalf of CytomX Therapeutics, Inc. Limited Shareholders
News Preview
New York, New York--(Newsfile Corp. - May 27, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of CytomX Therapeutics, Inc. (NASDAQ: CTMX) alleging that the Company violated federal securities laws.Class Period: May 17, 2018 and May 13, 2020Lead Plaintiff Deadline: July 20, 2020Learn...
Themefolio
Profiler
Peergroup
© Newsfile
27.05.2020
CTMX
LISTED
NASDAQ
Lead Plaintiff Deadline Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In CytomX Therapeutics, Inc. To Contact The Firm
News Preview
New York, New York--(Newsfile Corp. - May 27, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in CytomX Therapeutics, Inc. (NASDAQ: CTMX) ("CytomX" or the "Company") of the July 20, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the...
Themefolio
Profiler
Peergroup
© Newsfile
27.05.2020
CTMX
LISTED
NASDAQ
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of CytomX Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 20, 2020 - CTMX
News Preview
New York, New York--(Newsfile Corp. - May 26, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of CytomX Therapeutics, Inc. (NASDAQ: CTMX) ("CytomX") between May 17, 2018 and May 13, 2020. You are hereby notified that a securities class acti...
Themefolio
Profiler
Peergroup
© Newsfile
26.05.2020
CTMX
LISTED
NASDAQ
CytomX Therapeutics Shareholder Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In CytomX Therapeutics, Inc. To Contact The Firm
News Preview
New York, New York--(Newsfile Corp. - May 26, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in CytomX Therapeutics, Inc. (NASDAQ: CTMX) ("CytomX" or the "Company") of the July 20, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Compan...
Themefolio
Profiler
Peergroup
© Newsfile
25.05.2020
CTMX
LISTED
NASDAQ
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of CytomX Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 20, 2020 - CTMX
News Preview
New York, New York--(Newsfile Corp. - May 25, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of CytomX Therapeutics, Inc. (NASDAQ: CTMX) ("CytomX") between May 17, 2018 and May 13, 2020. You are hereby notified that a securities class...
Themefolio
Profiler
Peergroup
© Newsfile
24.05.2020
CTMX
LISTED
NASDAQ
CytomX Therapeutics Deadline Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In CytomX Therapeutics, Inc. To Contact The Firm
News Preview
New York, New York--(Newsfile Corp. - May 23, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in CytomX Therapeutics, Inc. (NASDAQ: CTMX) ("CytomX" or the "Company") of the July 20, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the...
Themefolio
Profiler
Peergroup
© Newsfile
22.05.2020
CTMX
LISTED
NASDAQ
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In CytomX Therapeutics, Inc. To Contact The Firm
News Preview
New York, New York--(Newsfile Corp. - May 22, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in CytomX Therapeutics, Inc. (NASDAQ: CTMX) ("CytomX" or the "Company") of the July 20, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Compan...
Themefolio
Profiler
Peergroup
© Newsfile
22.05.2020
CTMX
LISTED
NASDAQ
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of CytomX Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 20, 2020 - CTMX
News Preview
New York, New York--(Newsfile Corp. - May 22, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of CytomX Therapeutics, Inc. (NASDAQ: CTMX) ("CytomX") between May 17, 2018 and May 13, 2020. You are hereby notified that a securities class action la...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
